ARRY380
CAS No. 937265-83-3
ARRY380 ( ARRY-380 analog; ONT380 analog; ONT 380 analog; ONT-380 analog )
Catalog No. M16714 CAS No. 937265-83-3
ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 63 | In Stock |
|
5MG | 105 | In Stock |
|
10MG | 168 | In Stock |
|
25MG | 284 | In Stock |
|
50MG | 422 | In Stock |
|
100MG | 618 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameARRY380
-
NoteResearch use only, not for human use.
-
Brief DescriptionARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM.
-
DescriptionARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.
-
SynonymsARRY-380 analog; ONT380 analog; ONT 380 analog; ONT-380 analog
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR; HER2; p95-HER2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number937265-83-3
-
Formula Weight569.63
-
Molecular FormulaC29H27N7O4S
-
Purity>98%(HPLC)
-
SolubilityDMSO: > 10mM
-
SMILESCC1=C(OC2=CC3=NC=NN3C=C2)C=CC(NC2=NC=NC3=C2C=C(C=C3)C2=CC=C(CNCCS(C)(=O)=O)O2)=C1
-
Chemical Name6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Madala SK, et al. Am J Respir Cell Mol Biol. 2012 Mar;46(3):380-8.
molnova catalog
related products
-
RO 46-8443
RO 46-8443 is the first non-peptide endothelin ETB receptor selective antagonist. RO 46-8443 displays up to 2000-fold selectivity for ETB receptors both in terms of binding inhibitory potency and functional inhibition.
-
Sodium Nitroprusside...
Sodium Nitroprusside Dihydrate is a potent vasodilator working through releasing NO spontaneously in blood.
-
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).